Evidence map›Paper›PMID 37445695›Full record

ArticleInternational journal of molecular sciences2023

Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity.

Fernanda Caroline Coirada, Edgar Ruz Fernandes, Lucas Rodrigues de Mello, Viviane Schuch, Gúbio Soares Campos, Carla Torres Braconi, Silvia Beatriz Boscardin, Daniela Santoro Rosa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Fernanda Caroline CoiradaDepartamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo 04023-062, Brazil.ORCID 0000-0001-7512-3556
Edgar Ruz FernandesDepartamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo 04023-062, Brazil.ORCID 0000-0001-5981-5149
Lucas Rodrigues de MelloDepartamento de Biofísica, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo 04044-020, Brazil.
Viviane SchuchDepartamento de Análises Clínicas e Toxicológicas, Universidade de São Paulo (USP), São Paulo 05508-000, Brazil.
Gúbio Soares CamposLaboratório de Virologia, Universidade Federal da Bahia (UFBA), Salvador 40110-909, Brazil.
Carla Torres BraconiDepartamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo 04023-062, Brazil.ORCID 0000-0002-5370-8980
Silvia Beatriz BoscardinDepartamento de Parasitologia, Universidade de São Paulo (USP), São Paulo 05508-000, Brazil.ORCID 0000-0002-7845-7110
Daniela Santoro RosaDepartamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo 04023-062, Brazil.ORCID 0000-0003-4536-891X
Universidade Federal de São Paulo · BRUniversidade de São Paulo · BRInstituto Nacional de Ciência e Tecnologia em Entomologia Molecular · BRUniversidade Federal da Bahia · BR

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior Finance code 001National Council for Scientific and Technological Development 440721/2016-4São Paulo Research Foundation 2017/17471-7São Paulo Research Foundation 2018/07142-9São Paulo Research Foundation 2021/13004-0
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) has become a significant public health concern due to the increasing number of outbreaks worldwide and the associated comorbidities. Despite substantial efforts, there is no specific treatment or licensed vaccine against CHIKV to date. The E2 glycoprotein of CHIKV is a promising vaccine candidate as it is a major target of neutralizing antibodies during infection. In this study, we evaluated the immunogenicity of two DNA vaccines (a non-targeted and a dendritic cell-targeted vaccine) encoding a consensus sequence of E2

Indexed as

Chikungunya virusVaccines, DNAViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesDNAImmunity, CellularMiceAntibodies, NeutralizingAntibodies, ViralDNAVaccines, DNAViral VaccinesadjuvantsCHIKVDNA vaccineenvelopeheterologous prime-boostrecombinant proteinsingle chain

Identifiers

PMID37445695
PMCPMC10342165
OpenAlexW4381799097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.